TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of participants with adverse events after second vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Exacerbations rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exacerbations free interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet aggregation in response to arachidonic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Basophil activation tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Complete Self-reported Tobacco Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact on intestinal microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Local Injection Site Reaction Scale
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Decrease in White Blood Cell Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Collection Efficiency (CE) for WBC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: functional recovery of SICH patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Alleviation of Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of cytokines in cerebrospinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sustained Viral Response 12 Weeks After Last Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average QTcF change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes of Visual learning test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of Visual working memory test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of Verbal learning test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Western Ontario and McMaster Universities Index (WOMAC index)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Knee Society Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Time-Up-Go (TUG) test
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean Change in Intraocular Pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with blood pressure decrease more than 20% of the baseline value or systolic pressure less than 100 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: The number of cases who develop delirium
Endpoint domain: Adverse events/effects
Primary endpoint: Prognosis/Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Atopic symptoms severity (SCORAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Present Children for HIV Testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Days Participants Take to Bring Children for HIV Testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Calibration of kinetic models
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in basal metabolic rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Malignant transformation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of patients receiving high risk prescriptions
Endpoint domain: Adverse events/effects
Primary endpoint: Time to first occurrence of fatal or non-fatal ischemic stroke
Endpoint domain: Mortality/survival
Primary endpoint: Change in tobacco use intentions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in tobacco use attitudes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in smoking refusal intentions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Glaucoma medication usage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Failure rate of complex genitourinary reconstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Wound infection/separation
Endpoint domain: Adverse events/effects
Primary endpoint: Subjective Effects Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fertilization rate of oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Implantation rate of embryos
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Cheek cutaneous moisturization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in urine loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Participants With a ≥2 Point Improvement in Glabellar Line Scale (GLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone remodeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clarity of retinal images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Success of Neuraxial Block Placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neck Function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Disability of the Arm, Shoulder and Hand (DASH)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mortality and Morbidity
Endpoint domain: Mortality/survival
Primary endpoint: Change in Convulsive Seizure Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Cerebral oxygenation measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended Phase II Dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants With Objective Response According to RECIST v1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Quality of life - physical function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: In-stent Late Lumen Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bone parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Postoperative cognitive recovery
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Child Sunburn Occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pain Relief
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Presence of SARS-CoV-2 infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Insulin response and sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: pharmacokinetics of extended-release OROS paliperidone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported ratings of satiety
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Deaths Due to Adverse Events (AEs)
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of Participants With Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Participants With Cytokine Release Syndrome (CRS) by Grade of Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Mean serum concentration of serum amyloid A (SAA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of serum concentrations of SAA to pulmonary function test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Correlation of serum concentrations of SAA to radiologic extent of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Amount of maxillary molars distalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Symptoms of ADHD and Emotional and Behavioral Problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Plasma globotriaosylsphingosine (lyso-GL3) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Median Percentage of HbF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: BAROS psychometric test scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants with grade 2 or more acute intestinal toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Exercise Capacity: VO2peak (Maximal Oxygen Consumption)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change In Time To Exhaustion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of samples fulfilling microbiological standards
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Symptomatic Radiation Necrosis
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of successful abortion by 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Rate of successful abortion by 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: H-SIL Resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: H-SIL Regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants With a Decrease in Hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Uptake of 68Ga-exendin in the pancreas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of ovarian cancer and related cancers
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of clinically occult ovarian cancer and fallopian tube cancer
Endpoint domain: Mortality/survival
Primary endpoint: Positive predictive value and specificity of ROCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Physical Performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Penile blood flow contribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Compliance with exercise program
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Feasibility of exercise program
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Periodontal pocket probing depth (PD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival recession depth (RD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Grade 3-5, Treatment-Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants who perform app-based home 6MWT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tissue recognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hepatic changes (histological)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Responders at Month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Endometrial Gene Expression Profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asymptomatic retinal atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Asymptomatic optic nerve demyelinating lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intravitreous cytokine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diuretic Efficacy Index 1 for Sodium Excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diuretic Efficacy Index 2 for Water Excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in mitochondrial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thickness of undestroyed parenchyma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Center of Pressure, Path Length Per Second
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Center of Pressure, Standard Deviation (Y)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toy Interaction - Grasp/Touch/Kick/Mouth Time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Eating behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hypochondriasis Yale-Brown Obsessive-Compulsive Scale (H-YBOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New episode of hypercapnic respiratory failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Decreased UPCR (Urine Protein Creatinine Rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Progression determined by early PET scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of vosaroxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of cardiovascular anomaly
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pH of cough samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in Leicester Cough Questionnaire (LCQ) total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: SKAMP ADHD Rating Scale: Deportment Items
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Status of NK cell maturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants with Infusion Site Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with Markedly Abnormal Vital Signs Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Columbia-Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants with Potentially Clinically Significant Laboratory Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with Potentially Clinically Significant Electrocardiogram (ECG) Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to first seizure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Proportion of patients being seizure free
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Primary sustained clinical improvement at 12 months post-procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom of major limb adverse events at 12 months post-procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Power density spectrum peak frequency of uterine EMG bursts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum zonulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Peri-operative Blood Transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Exercise behavior and activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective report of exercise
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: safety and tolerability of patupilone
Endpoint domain: Adverse events/effects
Primary endpoint: potential activity of patupilone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preoperative serum testosterone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Risk for shoulder PJI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Bacterial load of deep tissue cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Postoperative Total Fentanyl Requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Interleukin (IL)-6 to IL-10 Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diabetes Health Literacy Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of Engagement in Diabetes-Related Health Behaviors
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Myasthenia Gravis Quality of Life 15-items (MG-QOL15)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Treatment Tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Composite Rate of Cardiac Death and Any Myocardial Infarction (MI)
Endpoint domain: Mortality/survival
Primary endpoint: incidence and severity of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: ICG transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pass/fail peanut challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent Surface Microhardness Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Arm movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of participants with treatment-related Adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Range of motion for the knee joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum electrolytes (Mg, K)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypoglycemic Fear Survey (HFS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Impact of Weight on Quality of Life (IWQOL-Lite)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 2-year progression-free survival (PFS) rates
Endpoint domain: Mortality/survival
Primary endpoint: expiratory oxygen fraction (end-tidal O2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Blood sampling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants Who Achieved Clinical Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of General peripheral neuropathy
Endpoint domain: Adverse events/effects
Primary endpoint: Reliability and validity of the EORTC QLQ-CR29
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pharmacokinetic parameters of digoxin (cmax, t 1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biomarkers of clinical utility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: copy number variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(IAsp) 0-12h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of neutrophile cells in induced sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of Interleukin 1beta in induced sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Metabolic Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline total body fat percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Patients With Cerebrovascular Events, Cardiovascular Events or Death
Endpoint domain: Mortality/survival
Primary endpoint: Participants Who Got New Diffusion-weighted Imaging (DWI) Lesions on Post-treatment Magnetic Resonance Imaging (MRI) Scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes